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SUPPLEMENTARY METHODS 
 
WELLCOME TRUST CASE CONTROL CONSORTIUM AND AFRICAN AMERICAN SAMPLE SELECTION 
The Wellcome Trust Case Control Consortium (WTCCC phase I) described the diagnosis and 
selection of T2D cases for the original study as “based on either current prescribed treatment with 
sulphonylureas, biguanides, other oral agents and/or insulin or, in the case of individuals treated 
with diet alone, historical or contemporary laboratory evidence of hyperglycaemia (as defined by 
the World Health Organization)”1. The two pooled control groups from the 1958 Birth Cohort 
(aged 44-45) and the UK Blood Service (aged 18-69) are used as shared controls for all seven 
disease cases (including T2D) in the original study1, which implies that the controls cannot be 
assumed to be group matched by BMI, age or sex.  The WTCCC2 (phase II) indirectly describes 
case selection in relation to the Metabochip array design2, which targets T2D genomic disease loci 
identified by the DIAGRAM consortium3. Although the T2D diagnostic criteria used by the >20 
participating research groups varied, most used ADA4; 5 and WHO6 guidelines and/or based on 
treatment with oral anti-diabetic medication or insulin3. The National Institute of Diabetes and 
Digestive and Kidney Diseases (NIDDK)7 recruited individuals with T2DM and End Stage Renal 
Disease (ESRD) from dialysis facilities, with the stipulation that cases had to meet at least one of 
the following three criteria to be included: i) T2DM diagnosed at least 5 years before initiating 
renal replacement therapy; ii) diabetic retinopathy and/or c) diabetic nephropathy (T2D-ESRD 
cases). 
Given the WTCCC groups did not specify if case and controls were matched by BMI, it cannot be 
ruled out that gene-mapping studies based upon these European samples might identify genetic 
loci that are confounded by BMI / adiposity rather than being associated with T2D alone. By 
contrast, this possibility is to some extent mitigated for this study, where the National Institute of 
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Diabetes and Digestive and Kidney Diseases (NIDDK)7 samples are BMI matched. WTCCC1 
used population controls, which (as noted in the publication1) reduces power due the control group 
including an expected proportion of T2D cases equal to the population prevalence. No published 
documentation for the selection of WTCCC2 controls is recorded8. For the NIDDK, unrelated 
African-American controls screened for no diagnosis of diabetes or renal disease were recruited 
from the community and internal medicine clinics (controls)7. This suggests that where 
cosmopolitan T2D disease loci (i.e. the co-location of disease loci for European and African 
American samples) are identified in this study, we can be more confident that these are not 
confounded by BMI/ adiposity. 
 
TARGETED RE-SEQUENCING - EUROPEAN CASE/CONTROL SAMPLES  
For the purposes of targeted re-sequencing at the loci ACTL7B, KCNK3 and TCF7L2, we used 
French samples with cases selected from multiplex families from linkage studies with a history of 
T2D9; 10 and unrelated controls selected from families with obese individuals, but no history of 
T2D11; 12 and 1:1 matched for age, sex and body mass index (BMI, see Table S2). 
 
CONSTRUCTION OF THE GENETIC LDU MAPS 
HapMap (Release 28) was used to construct genetic maps for the European samples using 56 
unrelated European (EUR) individuals genotyped for 2,270,218 SNPs (screened for quality 
control) and a second genetic map constructed for the African-American samples using 57 
unrelated individuals of African ancestry from South West USA (ASW) genotyped for 1,333,297 
quality-control SNPs.  The Linkage Disequilibrium (LD) maps are based upon HapMap data with 
genetic distance provided in additive LD units (LDU). The power of the multi-marker approach 
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compared with conventional GWA analysis (single-SNP tests) is primarily provided by the 
additional information contained in the high-resolution LDU genetic maps13-15 and the reduced 
number of genomic tests that reduces the multiple-testing burden. The construction of the LDU 
maps is based on the Malécot-Morton model, which describes the observed decline of pair-wise 
LD between SNPs as measured by rho, , as an exponential function of physical distance in 
kilobases (d). The expected decline in pairwise LD is modelled as:  ߩො = (1–L)Me–d + L, with M 
being the intercept, reflecting the maximum value of LD prior to LD breakdown (~1 for 
monophyletic origin, i.e. one ancestral haplotype) and L being the asymptote, reflecting spurious 
LD at large distance, not due to linkage. The parameter  is the exponential decline of LD and, 
together with distance d, in kb, an estimate of LDU = idi is provided for every ith interval.  In 
this way, all SNPs in the T2D datasets have genetic locations measured in LDU16. The parameters 
M, L and  are the iterative maximum likelihood estimations.  The autosomal genome was divided 
into 4,800 non-overlapping analytical windows of approximately equal size on the genetic map.  
 
ASSOCIATION MAPPING USING LDU MAPS 
We carried out association analyses for all autosomal chromosomes using three T2D datasets with 
a total of 5,800 cases and 9,691 controls. The first genome-wide association (GWA) dataset was 
obtained from the WTCCC (phase I) and included T2D cases (n=1,925) and controls (n=2,938) of 
North European ancestry with available genotypes (Affymetrix, ~500K SNPs)1; 2; 7. The second 
independent dataset was also from the WTCCC (phase II), and included T2D cases (n=2,910) and 
controls (n=5,724) of North European ancestry (UK)2, who were genotyped using the Metabochip 
array (Illumina, ~200K SNPs). The third dataset was obtained from a GWA study for a population 
of predominantly African ancestry conducted by the NIDDK7 and included African American 
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(AA) T2D cases (965) and AA controls (1029). The AA NIDDK T2D cases and controls were 
genotyped at a much higher SNP resolution array (Affymetrix, ~1M SNPs)7. All three datasets 
were screened using standard quality control filters described in previous publications1; 2; 7 and 
online data sources. For the eQTLs analysis we used data generated by the MuTHER consortium17. 
Subcutaneous adipose mRNA levels were measured in 825 European twins (TwinsUK) by the 
MuTHER consortium with data generation and normalization methods described in their initial 
report and online data sources17.  
 
The multi-marker association test18 is based on composite likelihood (Λ)16; 19, in which all observed 
genotyped SNPs within each window are simultaneously tested. We therefore do not use 
imputation and conditional analysis, because the aim of LDU analysis is to estimate the location 
of functional variants in any given genomic region that provides the strongest evidence of 
association with disease. For this approach observed (not imputed missing) genotype data are 
required for reasons explained in the main manuscript. Application of this method to each 
analytical window returns one estimated location (Ŝ) for the causal variant (± standard error) at the 
strongest signal, along with the association test P-value. The association test is based upon the 
same Malécot model used to construct the LDU maps described above, although in this case the 
T2D-by-SNP association (z)14 is included in the model instead of SNP-by-SNP association (, 
along with an additional parameter of causal variant location (Ŝ), with all distances measured in 
LDU. Therefore the Malécot model prediction of association between disease and markers is 
estimated by the equation ẑi = (1-L)Me-|(Si - Ŝ)| + L, where Si the ith SNP LDU location and Ŝ the 
estimated location of the putative functional variant on the genetic LDU map. The genetic distance 
standard errors of Ŝ were used to obtain the 95% confidence intervals (CI) of the putative causal 
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variants14, but in this study we only present the co-location intervals (distance between the Ŝ 
location estimates), which are the genomic regions within the CIs that most plausibly include the 
functional variants that confer risk of T2D. For the three gene regions used as examples (Figures 
2, 3 and 4 in the manuscript), we constructed LDU maps from the 1000 Genomes Project data, but 
no differences on the T2D locations estimates were observed based upon the 1000G and HapMap 
LDU maps.  
 
The regression coefficient b was used instead of z for the adipose expression quantitative 
phenotype (eQTL analysis).  All the regression coefficients, standard errors and P-values for 
expression probes regressed upon SNPs and probe corresponding gene names were obtained from 
the MuTHER website (http://www.muther.ac.uk). Our eQTL analysis targeted 173 replicated T2D 
signals (111 additional loci in Table 1, 62 from the previously found list20). The Malécot model 
was then applied after assigning the EUR LDU locations to the SNPs used from the MuTHER data 
for these 173 signals. The MuTHER probe gene names were updated based on common 
nomenclature as provide by the UCSC website and to be consistent with the publications that we 
have referenced in the manuscript. 
 
For convenience, all the functional location estimates (Ŝ) for T2D and eQTLs were converted back 
to the physical map Build 36 (B36, NCBI36/hg18) in kb by linear interpolation of the two flanking 
SNPs on the HapMap LDU map. When the Ŝ was located in an LDU block (horizontal LDU line) 
then all markers within that block have the same LDU location. In such cases, we took the midpoint 
of that block as an estimate of Ŝ in kb. All eQTL locations (Ŝ) had to co-locate within 50kb from 
the T2D Ŝ estimates. A detailed description of the Malécot multi-marker test of association is 
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provided by Maniatis et al.18 and the construction of the LDU maps for this study using the 
HapMap phase II data are described in more detail elsewhere14; 16. 
 
Analytical window P-values were meta-analysed using Fisher’s method to provide overall 
evidence of association. We did not use other types of meta-analysis (e.g. fixed or random effects), 
because the multi-marker test of association estimates the causal variant location, but not the 
association effect size. In order to account for multiple testing, analytical windows were filtered 
for having a meta P-value less than the Bonferroni corrected, genomic P-value threshold of 1x10–
5, based on the total number of tests performed (n=4,800;  = 0.05/4,800). Loci were only 
considered biologically plausible if the significant Ŝ location estimates from different datasets were 
within a <100 kb interval. 
 
For the eQTL analysis, adipose tissue expression probes were tested for cis-association and co-
localization, with cis defined in this study to be within 1.5 Mb distance either side of the 
replicated T2D causal location estimate. This approach provided eQTL location estimates on the 
LDU maps after Bonferroni correction for the total number of probes tested per 3Mb window. If 
the eQTL location estimate was within 50kb of the disease susceptibility location, this locus was 
considered to be a disease eQTL (i.e. associated with both T2D and cis-gene expression) and only 
these eQTL are presented in the result tables. The results table includes a column for the list of cis-
genes regulated by identified T2D disease loci.   
 
Here we make an important distinction between an eQTL and an eSNP, which relates to ability to 
make functional inferences about disease loci. In this study an eQTL is defined by a location 
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estimate for a putative functional variant(s) that regulates gene expression levels for one or more 
neighbouring genes in a relevant tissue and is associated with T2D. In other words, a potential 
molecular mechanism is immediately suggested for how risk may be conferred by a disease locus, 
which previously was unknown. By contrast, an eSNP study is defined only by the location of a 
SNP that is most strongly associated with neighbouring gene expression levels (and may or may 
not be associated with disease). For eSNP studies, the problems of inconsistency between different 
lead SNPs associated with disease and expression, between different arrays and across different 
populations can only be indirectly addressed using genotype imputation methods21; 22. For this 
study it has been established that the majority of the 111 additional susceptibility loci are also 
eQTLs. This implies that these disease loci may confer risk of T2D, at least in part, via the cis-
regulation of expression levels for a large number of neighbouring genes (conservatively, a total 
of 173 genomic disease loci, both new and previously known, that regulate the expression levels 
of a further 266 cis-genes). 
 
Our final set of cis-genes (from Tables 1, 2 and S1) were then further investigated in order to 
identify which adipose and liver gene expression profiles have previously also shown evidence of 
association with body mass index (BMI), a well-established co-morbidity of T2D. We used the 
results generated by an independent gene expression study23 which was based upon 701 
subcutaneous adipose and liver samples collected at Massachusetts General Hospital (MGH study) 
from morbidly obese individuals (BMI >30) who underwent Roux-en-Y gastric bypass surgery.  
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PREVIOUSLY KNOWN T2D LOCI 
We also analysed 76 previously known T2D loci20 to obtain refined location estimates on the same 
genetic maps. For these loci, we undertook commensurable association analyses by centralising 
the analytical window on the reported lead SNP. These 76 windows were then examined using the 
same procedures described above to identify T2D locations and assess whether these are eQTL or 
not. We confirmed 62 out of 76 loci (signals 112-173) and provide T2D location estimates along 
with associated cis-regulated genes in the supplementary Table S1 (including one, signal 174, from 
our previous work24). Results from the further investigation of the TCF7L2 locus (signal 117) are 
provided in the main manuscript. Other notable examples from the supplementary Table S1 are 
the HHEX (signal 149, [MIM: 604420]) and FTO (signal 152, [MIM: 610966]). HHEX is observed 
to regulate MARCH5 [MIM: 610637] expression levels, which codes for a mitochondrial E3 
ubiquitin-protein ligase that plays a crucial role in the control of mitochondrial morphology by 
acting as a positive regulator of mitochondrial fission25. This is the first time a mitochondrial 
fission gene has been implicated as a risk factor for metabolic disease. Despite testing T2D and 
not obesity, we observed FTO to also be a European T2D disease susceptibility locus with a co-
located eQTL that regulates IRX326 [MIM: 612985]. It is possible this observed association may 
reflect that the Wellcome Trust T2D cases for this study are overweight and/or poorly matched for 
BMI with the controls1; 2. However, we do not present this result in the table, because while 
nominally significant (P=0.03) and similar to previous studies26, the eQTL location for IRX3 did 
not pass Bonferroni correction for the total number of probes tested for this window. We also 
observed an eQTL within the promoter of IRX3 that regulates IRX5 [MIM: 606195], but we did 
not further investigate the regulatory landscape of IRX3, since the focus of this study was to 
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identify T2D loci that are also eQTL. The IRX3 was not observed to be associated with T2D either 
for this or in other studies.  
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Supplementary Figure S1: No relationship between the distance of the eQTL to the nearest 
gene (Y-axis) and the distance of the eQTL from the corresponding cis-regulated gene (X-axis). 
 
This regression analysis plot demonstrates that the practice of giving the nearest genes in GWA 
studies is misleading, since the implicated functional genes the eQTLs regulate are just as likely 
to be distant or near to the eQTL. The same analysis of the Y and X variables, but only including 
signals where the distance between T2D sample location estimates (Tables 1 and 2) were < 5kb 
yielded the same result (P>0.05). 
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Supplementary Figure S2: No relationship between the distance of the eQTL to the T2D 
location (Y-axis) and the distance between T2D sample location estimates (X-axis; i.e. between 
EUR and AA in Table 1 and between the two EUR samples in Table 2). 
  
This regression analysis plot shows no relationship between eQTL co-location and disease co-
location and demonstrates that the threshold of <100kb used as the criterion for considering 
estimated disease loci to be co-located and replicated, does not introduce any bias compared to 
the more conservative threshold of <50kb for the co-location of disease and eQTL.   
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Table S1. Refined information on the previously known T2D loci and their regulatory role of neighbouring gene expression 
All locations and distances are given in build 36; ¶Replication with the WTCCC (W), NIDDK AA (A), Metaboship (M) datasets; aT2D associated intervals in kb (<100) that harbour T2D 
locations between datasets; bLocation estimates for the European (E) GWAS;  cLocation estimates for the African-American (A) GWAS;  dLocation estimates for the Metaboship European (E) 
samples, signals with low SNP coverage ‘-’ were not meta-analysed;  eGenes in bold denote the intragenic localization and genes with ‘+’ for self-regulatory;  fNumber of cis-genes regulated 
by the eQTL;  gList of cis-genes associated with eQTLs that co-located within <50kb of the T2D locations on the genetic maps; cis-genes with ‘*’ have previously shown evidence of 
association between Body Mass Index for morbidly obese and adipose/liver expression profiles23; hDistance in kb (<50) between eQTL and T2D locations, the minimum is given when more 
than one cis-gene is implicated. Previously observed loci for signals 112-173 are derived from20 and signal 174 from24. 
Signal 
Known 
locus Lead SNP 
Lead 
SNP 
b36 chr Data¶ 
Meta 
P-value 
Distance 
between 
locationsa 
T2D 
location 
GWAS-Eb 
T2D 
location 
GWAS-Ac 
T2D 
location 
metabo-Ed 
Nearest gene to  
T2D locationse 
no. of 
cis-
genesf eQTL associated cis-genesg 
eQTL 
distance 
from 
T2Dh 
112 BCL11A rs243088 60422 2p WAM 4.22E-34 0 60441 60427 60441 MIR4432 1 PEX13 31 
113 TMEM154 rs6813195 153740 4q WAM 1.38E-08 1 153747 153739 153740 TMEM154  0 - - 
114 ANKRD55 rs459193 55843 5q WAM 2.15E-14 2 55834 55926 55832 LOC101928448 0 - - 
115 CDKAL1 rs7756992 20788 6p WAM 5.99E-180 0 20787 20750 20787 CDKAL1 0 - - 
116 CDKN2A/B rs944801 22042 9p WAM 8.16E-41 1 21987 21986 22022 CDKN2A/B 2 KIAA1797, MTAP 26 
117 TCF7L2 rs7903146 114748 10q WAM 3.55E-86 9 114736 114745 114737 TCF7L2 1 GPAM 28 
118 RBMS1 rs7569522 161055 2q WA 4.42E-21 95 160935 160840 >100kb RBMS1 1 RBMS1* 4 
119 KCNK16 rs1535500 39392 6p WA 1.04E-07 86 39505 39419 - KIF6 0 - - 
120 ZFAND6 rs11634397 78219 15q WA 1.95E-03 67 78193 78126 - ZFAND6 0 - - 
121 TMEM163 rs6723108 135196 2q AM 3.54E-12 1 >100kb 135313 135312 ACMSD 0 - - 
122 KCNQ1 rs231361 2648 11p AM 1.96E-14 15 ns 2648 2663 KCNQ1 0 - - 
123 KCNJ11 rs5215 17365 11p AM 5.32E-26 2 ns 17384 17382 ABCC8 2 MYOD1, UEVLD 0 
124 HNF1B rs4430796 33172 17q AM 1.21E-11 30 ns 33135 33165 HNF1B 0 - - 
125 PSMD6 rs12497268 64065 3p A 1.87E-05 - >100kb 63759 - C3orf49 0 - - 
126 HMGA2 rs2261181 64499 12q A 5.53E-03 - >100kb 64404 ns RPSAP52 0  - 
127 MAEA rs6815464 1300 4p A 1.84E-03 - ns 1267 ns MAEA 3 CTBP1, KIAA1530, CRIPAK* 8 
128 ANK1 rs516946 41638 8p A 7.57E-07 - ns 41608 - AGPAT6  1 ANK1 14 
129 TLE4 rs13292136 81142 9q A 2.97E-02 - ns 81146 - CHCHD9 0 - - 
130 FAF1 rs17106184 50683 1p A 5.38E-02 - ns 50894 - FAF1 2 EPS15, TXNDC12* 4 
131 BCAR1 rs7202877 73805 16q A 2.92E-03 - ns 73490 - WDR59 1 FA2H 16 
132 SRR rs2447090 2246 17p A 2.28E-07 - ns 2039 - SMG6 7 SRR, RPA1,CAMKK1, ZZEF1, 
TSR1, SMG6*, TMEM93 
0 
133 PEPD rs8182584 38602 19q A 7.27E-03 - ns 38543 - CEBPG 0 - - 
134 ADCY5 rs11717195 124565 3q WM 3.23E-23 7 124531 >100kb 124538 ADCY5 2 SEC22A, CCDC14* 15 
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rs3130501 
 
31244 
 
 
6p 
 
 
WM 
 
 
3.21E-35 
 
 
4 
 
 
31773 
 
 
>100kb 
 
 
31777 
 
 
LINC00243 
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LST1, LY6G6C, C6ORF25, MSH5, 
SLC44A4*, VARS2, DDR1, FLOT1, 
ABCF1, HLA-DQB2, TAP2*, 
TRIM15, TRIM40 
0 
 
 
 
136 DGKB rs6960043 15019 7p WM 3.90E-47 2 15034 >100kb 15032 DGKB 0 - - 
137 TSPAN8 rs7955901 69720 12q WM 4.01E-37 11 69867 >100kb 69878 TSPAN8  2 LRRC10, FRS2 0 
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MPHOSPH9 
 
 
rs4275659 
 
 
122014 
 
 
12q 
 
 
WM 
 
 
4.46E-05 
 
 
61 
 
 
121953 
 
 
>100kb 
 
 
122014 
 
 
VPS37B, ABCB9+ 
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DNAH10, PITPNM2, ABCB9, 
VPS37B, TMED2, RSRC2, 
ZCCHC8, NCOR2, DIABLO 
0 
 
 
139 HMG20A rs7177055 75620 15q WM 2.25E-04 40 75058 >100kb 75098 PSTPIP1 2 HMG20A, TSPAN3  0 
140 IRS1 rs7578326 226729 2q WM 3.08E-41 59 226788 ns 226729 LOC646736 0 - - 
141 PPARG rs13081389 12265 3p WM 4.33E-17 18 12311 ns 12292 PPARG 1 WNT7A 6 
142 ADAMTS9 rs6795735 64680 3p WM 1.01E-13 1 64707 ns 64706 ADAMTS9 0 - - 
143 IGF2BP2 rs4402960 186994 3q WM 1.89E-23 1 187031 ns 187032 IGF2BP2 0 - - 
144 ARL15 rs702634 53307 5q WM 2.85E-04 99 53347 ns 53248 ARL15 1 FST* 19 
145 ZBED3 rs6878122 76463 5q WM 1.81E-11 0 76457 ns 76457 ZBED3 1 PDE8B* 16 
146 JAZF1 rs849135 28163 7p WM 2.51E-67 90 28226 ns 28136 JAZF1 0 - - 
147 KLF14 rs13233731 130088 7q WM 2.59E-06 46 130074 ns 130120 KLF14  0 - - 
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148 
 
TP53INP1 
 
rs7845219 
 
96007 
 
8q 
 
WM 
 
1.28E-11 
 
97 
 
96132 
 
ns 
 
96035 
 
NDUFAF6, TP53INP1 
 
6 
 
GDF6, GEM, MTERFD1, 
FAM92A1, C8orf37, KIAA1429 
0 
 
149 HHEX/IDE rs1111875 94453 10q WM 2.27E-61 21 94490 ns 94469 HHEX 1 MARCH5 1 
150 HNF1A rs12427353 119911 12q WM 3.79E-31 74 119794 ns 119720 SPPL3 1 MSI1 48 
151 
 
PRC1 
 
rs8042680 
 
89322 
 
15q 
 
WM 
 
3.68E-56 
 
59 
 
89245 
 
ns 
 
89304 
 
MAN2A2, RCCD1+ 
 
4 
 
RCCD1, UNC45A, IQGAP1*, 
FAM174B* 
1 
 
152 FTO rs9936385 52377 16q WM 2.52E-176 11 52368 ns 52357 FTO 0 - - 
153 MC4R rs12970134 56036 18q WM 5.19E-21 1 55879 ns 55880 RPS3A 0 - - 
154 GCKR rs780094 27595 2p M 2.16E-17 - >100kb >100kb 27228 TCF23 2 PLB1, KHK 6 
155 GCC1 rs17867832 126784 7q M 1.01E-02 - >100kb ns 126964 GCC1 1 IMPDH1 23 
156 NOTCH2 rs10923931 120319 1p M 1.42E-24 - ns ns 120238 ADAM30 0 - - 
157 PROX1 rs2075423 212221 1q M 1.71E-04 - ns ns 212226 PROX1 0 - - 
158 THADA rs10203174 43544 2p M 4.35E-15 - ns ns 43555 THADA 0 - - 
159 GRB14 rs13389219 165237 2q M 7.31E-03 - ns ns 165209 GRB14 1 SCN2A 32 
160 WFS1 rs4458523 6341 4p M 2.61E-46 - ns ns 6359 WFS1 3 GRPEL1, STK32B, KIAA0232 2 
161 SLC30A8 rs3802177 118254 8q M 6.10E-05 - ns ns 118251 SLC30A8 1 SAMD12 0 
162 GLIS3 rs10758593 4282 9p M 2.45E-10 - ns ns 4273 GLIS3 0 - - 
163 CDC123 rs11257655 12348 10p M 4.54E-06 - ns ns 12189 DHTKD1 0 - - 
164 ARAP1 rs1552224 72111 11q M 1.67E-03 - ns ns 72534 FCHSD2 1 POLD3 8 
165 CILP2 rs10401969 19269 19p M 1.35E-39 - ns ns 19188 NCAN 3 ATP13A1, KIAA0892, TM6SF2* 2 
166 GIPR rs8108269 50850 19q M 1.49E-04 - ns ns 51124 NOVA2 0 - - 
167 RND3 rs7560163 151346 2q W 4.53E-02 - 151248 ns - LOC101929282  0 - - 
168 SSR1 rs9505118 7235 6p W 4.31E-02 - 7229 >100kb - SSR1 1 BMP6 46 
169 ZMIZ1 rs12571751 80613 10q W 4.06E-04 - 80700 ns - ZMIZ1 1 DYDC2 9 
170 GRK5 rs10886471 121139 10q W 3.28E-02 - 121233 ns - RGS10  0 - - 
171 CCND2 rs11063069 4245 12p W 1.04E-02 - 4170 ns - CCND2 0 - - 
172 VPS26A rs1802295 70601 10q W 1.03E-02 - 70421 ns ns KIAA1279 1 HERC4 49 
173 C2CD4A rs4502156 60170 15q W 2.02E-02 - 59905 ns ns VPS13C  4 APH1B, RORA, VPS13C, TPM1 14 
174 ABCC5 - - 3q WA 1.00E-07 0 185136 185136 - ABCC5+ 1 ABCC5 0 
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Table S2.  Demographic characteristics for targeted re-sequence T2D case/ control European samples. 
 
       
Cases Variable Obs Mean Std Dev. Min Max 
       
       
Female Age 57 47.4 7.0 26.0 72.0 
 BMI 57 27.1 4.6 17.6 34.7 
Male Age 49 43.5 7.5 20.0 53.0 
 BMI 49 25.9 3.5 17.6 34.5 
       
Controls       
       
Female Age 57 47.8 7.3 26.0 72.0 
 BMI 57 27.7 4.0 21.1 34.8 
Male Age 49 40.7 7.1 20.0 53.0 
 BMI 49 27.0 3.6 18.7 34.5 
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